Effect of perindopril on the quality of life with comorbidity of obesity and coronary heart disease

Author(s):  S.V. Zhemchuzhikov, Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia

L.V. Vasilieva, Dr., Prof., Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia

E.V. Gosteva, candidate of Sciences, Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia

A.V. Nikitin, Dr., Prof., Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia

Issue:  Volume 42, № 3

Rubric:  Internal diseases

Annotation:  Currently, the increasing social importance of studying the quality of life of persons with obesity, in accordance with the national clinical guidelines for the diagnosis, treatment, prevention of obesity and associated diseases, the social importance of studying the quality of life. The aim of the work is to increase the effectiveness of treatment of patients with obesity and coronary heart disease (CHD) by including perindopril in therapy. Material. An open randomized study to improve the effectiveness of treatment of 84 patients with coronary heart disease in combination with obesity I-II art., of which 45 women and 39 men, the average age was (56,2 ± 4,8) years. Results. The patients were randomized into groups: the first – 42 patients received perindopril in the complex therapy at a dose of 10 mg per day for 6 months, the second – standard drug therapy. We used the Russian version of the SF-36 questionnaire. As a result of complex therapy in group 1, there was a significant (p < 0,05) increase in quality of life on five studied scales of the SF-36 questionnaire (General Health –by 16 points, 40 %; Vitality – by 15,9 points, 48 %; Physical Functioning – by 29,5 points, 85 %; Sosial Functioning – 10,2 points, 20 %; Role-Physical – 17,8 points, 45 %), the indicator of the pain intensity scale significantly decreased (Body Pain by 24 score, 48 %). In group 2, there was also an improvement in all indicators of quality of life, which did not reach the degree of reliability, a significant (p < 0,05) decrease by 35 % of the pain intensity index (17,4 points). Conclusion. An effective method of treatment of patients with CHD and obesity is the inclusion of perindopril 10 mg/day in this cohort of patients.

Keywords:  coronary heart disease, obesity, quality of life, perindopril

Full text (PDF):  Download

Downloads count:  498